Immune-mediated inflammation promotes subclinical atherosclerosis in recent-onset psoriatic arthritis patients without conventional cardiovascular risk factors

RODOLFO KÖLLIKER-FRERS; VANESA COSENTINO; JULIA TAU; EDUARDO KERZBERG; ADRIANA URDAPILLETA; MONICA CHIOCCONI; NORA KOGAN; OTERO-LOSADA, M.* (SHARED AUTHORSHIP); FRANCISCO CAPANI * (SHARED AUTHORSHIP)

Frontiers in Immunology

Lausanne : Frontiers Research Foundation

Lugar: Lausanne; Año: 2018

1664-3224

Studies on the inflammatory burden in recent-onset psoriatic arthritis (PsA) patients without conventional cardiovascular risk factors (CVRFs) are not available. This preliminary study focuses on cardiovascular risk in cutaneous psoriasis (CPs) and recent-onset PsA patients. Blood biochemistry (glucose, cholesterol, uric acid, lipid profile and apolipoprotein B) was analysed using standard kits. Pro-atherogenic inflammation markers, C-reactive protein (CRP) and interleukin-6 (IL-6), and endothelial activators monocyte chemoattractant protein-1 (MCP-1) and soluble intercellular adhesion molecule-1 (sICAM-1), were determined by ELISA. Ultrasound images allowed measuring carotid intima-media thickness (cIMT).Our study first shows an increase in cIMT, and in serum levels of sICAM-1 and CRP in recent-onset PsA patients not presenting conventional CVRFs over the non-medicated time-period, from disease diagnosis to the beginning of pharmacological treatment, compared with healthy subjects. The outcome highlights the importance of monitoring serum level of sICAM1, CRP, and cIMT, and the value of primary prevention in psoriatic patients even with no history of cardiovascular events.